InvestorsHub Logo
Followers 8
Posts 481
Boards Moderated 0
Alias Born 02/03/2021

Re: theswordman post# 171926

Thursday, 06/24/2021 11:30:02 PM

Thursday, June 24, 2021 11:30:02 PM

Post# of 232887
Right. As I see it, the fact that Leronlimab is not yet approved is our unfortunate situation for this LH scene because Dr. Patterson is doing parallel work with Maravoric that could have been done with LL. It doesn't mean that if he was with Cytodyn, somehow FDA would have approved LL any sooner for the severe/critical indication. Until that happens he would have had to do all this LH work independently.

However if we had good relations with him, we would have collaborations with him and he would have shared his LH discoveries and his guidance for us to build on with LL. Now we are forced to act as if we are completely independent of him and repeat things through other channels. Time and money. Ideally speaking, Nader should resolve any ego or power-conflicts and get him back on the board.

But it is what it is. We are on track now even if behind.

I see that Dr. Patterson is professional and his focus is the science and the treatment. He is not anti-LL or playing a short against us. He mentions LL freely and tweets of its potential if asked. So if Cytodyn establishes its efficacy for LH patients (gets approval) as a CCR5 antagonist, then Dr. Patterson would probably be open to its use as well. Down the road there should be a convergence.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News